These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 21341301)

  • 1. Designing a seamless phase II/III clinical trial using early outcomes for treatment selection: an application in multiple sclerosis.
    Friede T; Parsons N; Stallard N; Todd S; Valdes Marquez E; Chataway J; Nicholas R
    Stat Med; 2011 Jun; 30(13):1528-40. PubMed ID: 21341301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statistical aspects of the TNK-S2B trial of tenecteplase versus alteplase in acute ischemic stroke: an efficient, dose-adaptive, seamless phase II/III design.
    Levin B; Thompson JL; Chakraborty B; Levy G; MacArthur R; Haley EC
    Clin Trials; 2011 Aug; 8(4):398-407. PubMed ID: 21737464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flexible selection of a single treatment incorporating short-term endpoint information in a phase II/III clinical trial.
    Stallard N; Kunz CU; Todd S; Parsons N; Friede T
    Stat Med; 2015 Oct; 34(23):3104-15. PubMed ID: 26112909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adaptive seamless designs with interim treatment selection: a case study in oncology.
    Carreras M; Gutjahr G; Brannath W
    Stat Med; 2015 Apr; 34(8):1317-33. PubMed ID: 25640198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seamless phase II/III designs.
    Stallard N; Todd S
    Stat Methods Med Res; 2011 Dec; 20(6):623-34. PubMed ID: 20724313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Group-sequential methods for adaptive seamless phase II/III clinical trials.
    Stallard N
    J Biopharm Stat; 2011 Jul; 21(4):787-801. PubMed ID: 21516569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis.
    Chataway J; Nicholas R; Todd S; Miller DH; Parsons N; Valdés-Márquez E; Stallard N; Friede T
    Mult Scler; 2011 Jan; 17(1):81-8. PubMed ID: 20798135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adaptive Dunnett tests for treatment selection.
    Koenig F; Brannath W; Bretz F; Posch M
    Stat Med; 2008 May; 27(10):1612-25. PubMed ID: 17876763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
    Schmidli H; Bretz F; Racine-Poon A
    Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limb-Leaf designs for adaptive exploration of the dose-response curve.
    Spivack J; Cheng B; Levin B
    Contemp Clin Trials; 2018 Jan; 64():210-218. PubMed ID: 28988992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing the data combination rule for seamless phase II/III clinical trials.
    Hampson LV; Jennison C
    Stat Med; 2015 Jan; 34(1):39-58. PubMed ID: 25315892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal seamless phase 2/3 oncology trial designs based on Probability of Success (PoS).
    Teng Z; Liang L; Liu G; Liu Y
    Stat Med; 2018 Dec; 37(28):4097-4113. PubMed ID: 30084110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conditionally unbiased estimation in phase II/III clinical trials with early stopping for futility.
    Kimani PK; Todd S; Stallard N
    Stat Med; 2013 Jul; 32(17):2893-910. PubMed ID: 23413228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Data-driven treatment selection for seamless phase II/III trials incorporating early-outcome data.
    Kunz CU; Friede T; Parsons N; Todd S; Stallard N
    Pharm Stat; 2014; 13(4):238-46. PubMed ID: 24789367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seamless Phase II/III combination study through response adaptive randomization.
    Wang L; Cui L
    J Biopharm Stat; 2007; 17(6):1177-87. PubMed ID: 18027224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts.
    Bretz F; Schmidli H; König F; Racine A; Maurer W
    Biom J; 2006 Aug; 48(4):623-34. PubMed ID: 16972714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The inclusion of real world evidence in clinical development planning.
    Martina R; Jenkins D; Bujkiewicz S; Dequen P; Abrams K;
    Trials; 2018 Aug; 19(1):468. PubMed ID: 30157904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
    Jenkins M; Stone A; Jennison C
    Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A varying-stage adaptive phase II/III clinical trial design.
    Dong G
    Stat Med; 2014 Apr; 33(8):1272-87. PubMed ID: 24273128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Designing multi-arm multi-stage clinical trials using a risk-benefit criterion for treatment selection.
    Jaki T; Hampson LV
    Stat Med; 2016 Feb; 35(4):522-33. PubMed ID: 26456537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.